Mergers & Acquisitions
Jun. 19, 2015
Kythera Biopharmaceuticals taps Latham for $2.1B sale to Allergan
The deal comes as Kythera was preparing to launch its FDA-approved facial aesthetics drug.
Daily Journal Staff Writer
Kythera Biopharmaceuticals Inc., makers of an FDA-approved drug designed to reduce
neck fat, relied on longtime adviser Latham & Watkins LLP in its cash and equity sale
to Botox maker Allergan PLC, a deal announced Wednesday.
According to terms of the transaction, Kythera shareholders will receive $75 per share,
f...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In